Charming Medical Stock Fraud Lawsuit
Analysis based on 7 articles · First reported Jan 05, 2026 · Last updated Feb 06, 2026
The market is negatively impacted by the alleged fraudulent stock promotion scheme involving Charming Medical Limited, leading to a class action lawsuit and the halting of its stock trading. This event highlights risks for retail investors and could lead to increased scrutiny of social media-driven stock promotions by regulators.
A class action lawsuit has been filed against Charming Medical Limited by Bragar Eagel & Squire in the United States — United States District Court for the Northern District of California. The lawsuit alleges that Charming Medical Limited was involved in a fraudulent stock promotion scheme using social media misinformation and impersonated financial professionals. Insiders and/or affiliates are accused of using offshore or nominee accounts to dump shares during a price inflation campaign. The stock price of Charming Medical Limited surged from an IPO price of $4.00 to $29.36 per share without fundamental justification. The United States — United States Securities and Exchange Commission halted trading of Charming Medical Limited's stock on November 12, 2025, and it remains halted as the company has not provided the required information to lift the suspension. Investors who purchased Charming Medical Limited common stock between October 10, 2025, and November 12, 2025, are encouraged to contact Bragar Eagel & Squire to discuss their legal options.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard